Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug
Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements Crenessity, a Neurocrine drug approved for treating a rare endocrine disorder called congenital adrenal hyperplasia.
From Data Ownership to Learning Velocity in Direct-to-Consumer Healthcare
As commercialization increasingly reflects direct engagement dynamics, differentiation depends less on the volume of data controlled and more on the speed at which systems incorporate feedback.
Not All Hospitals Have Equal Resources — Knowledge Sharing Can Help Level the Playing Field
Resource-sharing across large networks of hospitals allows people to receive a higher quality of care across the country, regardless of where they live or how well-resourced their local health system may be.
Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics
Startup Pinnacle Medicines is developing peptide drugs with the same efficacy as biologic medicines and the dosing convenience of oral small molecules. The lead program of OrbiMed-incubated Pinnacle is on track to enter the clinic in asthma and chronic obstructive pulmonary disease.
What Will Separate Healthcare AI Winners From Losers?
Uma (Veerappan) Nuggehalli of Flare Capital Partners thinks the healthcare AI startups that will come out on top will be companies that integrate seamlessly into workflows, build proprietary datasets and quickly determine how to sell their technology.